Client Background:
The client offered point-of-care and laboratory-based diagnostic solutions, with an established biomarker portfolio spanning cardiovascular, kidney, and metabolic health. The company sought to expand into at-home testing for aging populations.
Challenges:
- Uncertainty around the commercial viability of a combined at-home diagnostic panel for aging populations.
- Limited clarity on high-potential user segments and willingness to adopt multiplex testing.
- Fragmented visibility into competing solutions and emerging diagnostic technologies.
- Regulatory, technological, and partnership gaps that could affect market entry.
Engagement Objective:
The engagement aimed to validate the business case for an at-home multiplex diagnostic panel, identify priority patient segments, benchmark competing solutions, and determine the requirements for successful product development and commercialization.
Approach:
The study aimed to provide a comprehensive evaluation of the at-home multiplex diagnostics opportunity through:
- Assessed disease burden, population needs, and market trends across the US and EU.
- Gathered patient, physician, and expert perspectives on testing preferences and adoption barriers.
- Examined existing solutions, emerging technologies, and relevant regulatory requirements.
- Modeled market scenarios and assessed potential entry pathways and partnership options.
Solutions Offered:
Market Sizing and Growth Estimation
We estimated market size across total addressable, serviceable, and pragmatically obtainable segments, along with growth projections across target disease areas. The sizing helped the client attain a fact-based view of commercial headroom, demand momentum, and geographic variation, enabling clearer comparison of at-home multiplex testing opportunities and a well-structured prioritization of product investment and market entry decisions across the target markets.
Patient Segment Prioritization
Prioritized patient segments based on unmet needs and adoption potential across the aging population. The evaluation analyzed disease burden, testing convenience, willingness to adopt at-home solutions, as well as payer expectations. It enabled the client to focus on segments likely to generate clinical value and commercial traction.
Competitive Benchmarking
Conducted competitive benchmarking of established and emerging diagnostic solutions across cost, market presence, usability, and performance. It helped clarify areas where at-home multiplex testing could differentiate versus lab-based and PoC alternatives.
Regulatory and Capability Analysis
Assessed regulatory requirements and technical capability gaps relevant to at-home multiplex testing. The analysis covered validation expectations, approval pathways, data-security considerations, and usability requirements while pinpointing internal capability limitations in connected devices, assay development, and care delivery.
Partnership and Development Roadmap
Identified partnership opportunities across the diagnostics, technology, and care-delivery ecosystem to accelerate market entry and eliminate capability gaps. Based on these insights, a product development roadmap was also delivered, covering pilot design, concept validation, partnership engagement, and scale-up readiness.
Client Impact:
- Quantified market potential and adoption scenarios across disease areas and geographies, prioritizing the approximately 20% of opportunities for product investment based on commercial viability and patient adoption potential.
- Identified the most viable at-home multiplex testing concept from multiple early-stage at-home testing ideas.
- Identified capability gaps and validated partnership opportunities across technology and care delivery ecosystem players.
- Mapped US and EU regulatory pathways to support early-stage product design and feasibility planning.
- Defined an initial development and validation pathway to guide pilot design and future scale-up decisions.
Outcome Snapshot:
